Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4738-4748

  Han, Chun ^a   Huang, Zhangjian ^a   Zheng, Chao ^b   Wan, Ledong ^a   Zhang, Lianwen ^c   Peng, Sixun ^a   Ding, Ke ^c   Ji, Hongbin ^b   Tian, Jide ^d   Zhang, Yihua ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETIC ACID; 3 [(2,5 DICHLOROPYRIMIDIN 4 YL)OXY]ANILINE; 4 [2 [2 [2 [4 [4 [[4 [3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY] ETHOXY]ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETAMIDO] ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY]ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [2 [4 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETYL] PIPERAZIN 1 YL]ETHOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [3 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETAMIDO] PROPOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [3 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY] PROPOXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [4 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY)BUTOXY)-3-(PHENYLSULFONYL)-1,2,5 OXADIAZOLE 2 OXIDE; 4 [[1 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETAMIDO] PROPAN 2 YL]OXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[1 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETYL]PIPERIDIN 4 YL]OXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[4 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY]BUT 2 YN 1 YL]OXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[6 [2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETOXY]HEXYL] OXY] 3 (PHENYLSULFONYL) 1,2,5 OXADIAZOLE 2 OXIDE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETHYL 2 [4 (3 METHOXY 4 NITROPHENYL)PIPERAZIN 1 YL]ACETATE; ETHYL 2 [4 (4 AMINO 3 METHOXYPHENYL)PIPERAZIN 1 YL] ACETATE; ETHYL 2 [4 [4 [[4 (3 ACRYLAMIDOPHENOXY) 5 CHLOROPYRIMIDIN 2 YL]AMINO] 3 METHOXYPHENYL]PIPERAZIN 1 YL]ACETATE; GEFITINIB; HEMOGLOBIN; N [3 [(2,5 DICHLOROPYRIMIDIN 4 YL)OXY]PHENYL]ACRYLAMIDE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; NITRIC OXIDE; OXADIAZOLES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84879055043     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400463q     Document Type: Article

References (40)

1. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 2000, 19, 3159-3167 (Pubitemid 30428195)
2. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer Semin. Oncol. 2006, 33, 369-385 (Pubitemid 44142736)
3. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004, 304, 1497-1500 (Pubitemid 38720929)
4. Le, L. H.; Chetty, R.; Moore, M. J. Epidermal growth factor receptor expression in anal canal carcinoma Am. J. Clin. Pathol. 2005, 124, 20-23 (Pubitemid 40944369)
5. Hayashi, Y.; Ueki, K.; Waha, A.; Wiestler, O. D.; Louis, D. N.; von Deimling, A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme Brain Pathol. 1997, 7, 871-875 (Pubitemid 27346731)
6. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013 Ca-Cancer J. Clin. 2013, 63, 11-30
7. Herbst, R. S.; Heymach, J. V.; Lippman, S. M. Lung cancer New Engl. J. Med. 2008, 359, 1367-1380
8. Pao, W.; Girard, N. New driver mutations in non-small-cell lung cancer Lancet Oncol. 2011, 12, 175-180
9. Suda, K.; Tomizawa, K.; Mitsudomi, T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metastasis Rev. 2010, 29, 49-60
10. Gately, K.; O'Flaherty, J.; Cappuzzo, F.; Pirker, R.; Kerr, K.; O'Byrne, K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC J. Clin. Pathol. 2012, 65, 1-7
11. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Sarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg. Med. Chem. Lett. 2001, 11, 1911-1914 (Pubitemid 32675316)
12. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; Di Orio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnick, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Caner Res. 1997, 57, 4838-4848 (Pubitemid 27468992)
13. Ladanyi, M.; Pao, W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond Mod. Pathol. 2008, 21 (Suppl 2) S16-22
14. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, e73
15. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib New Engl. J. Med. 2005, 352, 786-792 (Pubitemid 40271173)
16. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075 (Pubitemid 351439466)
17. Janne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.; Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan, P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer J. Clin. Oncol. 2007, 25, 3936-3944 (Pubitemid 47477271)
18. Murakami, H.; Tamura, T.; Takahashi, T.; Nokihara, H.; Naito, T.; Nakamura, Y.; Nishio, K.; Seki, Y.; Sarashina, A.; Shahidi, M.; Yamamoto, N. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) Cancer Chemother. Pharmacol. 2012, 69, 891-899
19. Sequist, L. V.; Besse, B.; Lynch, T. J.; Miller, V. A.; Wong, K. K.; Gitlitz, B.; Eaton, K.; Zacharchuk, C.; Freyman, A.; Powell, C.; Ananthakrishnan, R.; Quinn, S.; Soria, J. C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 2010, 28, 3076-3083
20. Ramalingam, S. S.; Blackhall, F.; Krzakowski, M.; Barrios, C. H.; Park, K.; Bover, I.; Seog Heo, D.; Rosell, R.; Talbot, D. C.; Frank, R.; Letrent, S. P.; Ruiz-Garcia, A.; Taylor, I.; Liang, J. Q.; Campbell, A. K.; O'Connell, J.; Boyer, M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 2012, 30, 3337-3344
21. Riely, G. J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer J. Thorac. Oncol. 2008, 3, S146-149
22. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027 (Pubitemid 28460532)
23. Zhou, W. J.; Ercan, D.; Janne, P. A.; Gray, N. S. Discovery of selective irreversible inhibitors for EGFR-T790M Bioorg. Med. Chem. Lett. 2011, 21, 638-643
24. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
25. Fukumura, D.; Kashiwagi, S.; Jain, R. K. The role of nitric oxide in tumour progression Nat. Rev. Cancer 2006, 6, 521-534 (Pubitemid 43980541)
26. Bonavida, B.; Baritaki, S.; Huerta-Yepez, S.; Vega, M. I.; Chatterjee, D.; Yeung, K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 2008, 19, 152-157
27. Riganti, C.; Miraglia, E.; Viarisio, D.; Costamagna, C.; Pescarmona, G.; Ghigo, D.; Bosia, A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 2005, 65, 516-525
28. Sullivan, R.; Graham, C. H. Chemosensitization of cancer by nitric oxide Curr. Pharm. Des. 2008, 14, 1113-1123 (Pubitemid 351982558)
29. Nakanishi, C.; Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs Nat. Rev. Cancer 2005, 5, 297-309 (Pubitemid 40488635)
30. Chang, K.; Lee, S. J.; Cheong, I.; Billiar, T. R.; Chung, H. T.; Han, J. A.; Kwon, Y. G.; Ha, K. S.; Kim, Y. M. Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκB Exp. Mol. Med. 2004, 36, 311-324 (Pubitemid 39279527)
31. Bivona, T. G.; Hieronymus, H.; Parker, J.; Chang, K.; Taron, M.; Rosell, R.; Moonsamy, P.; Dahlman, K.; Miller, V. A.; Costa, C.; Hannon, G.; Sawyers, C. L. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR Nature 2011, 471, 523-526
32. Aguirre, G.; Boiani, M.; Cerecetto, H.; Fernandez, M.; Gonzalez, M.; Leon, E.; Pintos, C.; Raymondo, S.; Arredondo, C.; Pacheco, J. P.; Basombrio, M. A. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies Pharmazie 2006, 61, 54-59 (Pubitemid 43128776)
33. Chen, L.; Zhang, Y.; Kong, X.; Lan, E.; Huang, Z.; Peng, S.; Kaufman, D. L.; Tian, J. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid J. Med. Chem. 2008, 51, 4834-4838
34. Huang, Z.; Zhang, Y.; Zhao, L.; Jing, Y.; Lai, Y.; Zhang, L.; Guo, Q.; Yuan, S.; Zhang, J.; Chen, L.; Peng, S.; Tian, J. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid Org. Biomol. Chem. 2010, 8, 632-639
35. Ling, Y.; Ye, X.; Zhang, Z.; Zhang, Y.; Lai, Y.; Ji, H.; Peng, S.; Tian, J. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity J. Med. Chem. 2011, 54, 3251-3259
36. Kuntz, K.; Uehling, D. E.; Waterson, A. G.; Emmitte, K. A.; Stevens, K.; Shotwell, J. B.; Smith, S. C.; Nailor, K. E.; Salovich, J. M.; Wilson, B. J.; Cheung, M.; Mook, R. A.; Baum, E. W.; Moorthy, G. Preparation of imidazopyridines as inhibitors of IGF-1R and IR and one or both of EGFR and ErbB2 kinases for treating neoplasm. U.S. Pat. Appl. Publ. US 20080300242, 2008.
37. Jares-Erijman, E. A.; Jovin, T. M. FRET imaging Nat. Biotechnol. 2003, 21, 1387-1395 (Pubitemid 37356626)
38. 790 mutant J. Med. Chem. 2012, 55, 2711-2723
39. Coneski, P. N.; Schoenfisch, M. H. Nitric oxide release: part III. Measurement and reporting Chem. Soc. Rev. 2012, 41, 3753-3758
40. Fukumura, D.; Kashiwagi, S.; Jain, R. K. The role of nitric oxide in tumour progression Nat. Rev. Cancer 2006, 6, 521-534